at their broadest reach, food standards covered nearly 45 percent of the wholesale value of food shipped in interstate commerce, excluding fresh fruits and vegetables).
INTRODUCTION
Imagine Jane, a typical consumer in 1966. When shopping for food, she has relatively few choices within each product category; nearly half of the nation's food products-including staples such as milk, cheese, bread, and jam-are subject to FDA-imposed recipe-style standards of identity that allow little variation.
1 Food labels contain barely any useful information. There is no "Nutrition Facts" panel. The labeling of standardized foods does not even state the ingredients. Nutrient content descriptors are rare; indeed, FDA prohibits any reference whatsoever to cholesterol. 2 Claims regarding foods' usefulness in preventing disease are also virtually absent from labels; FDA considers any such statements to render the product an unapproved, and thus illegal, drug. The same is true for any claims regarding a food's effect on the structure or function of the body. 3 If Jane wants to purchase fortified food, her choices are limited. Although more foods are fortified with vitamins and minerals than had been the case during World War II, the spread of fortification has been stalled by FDA's vigorous efforts to restrict the practice. 4 The agency is also endeavoring to restrict Jane's choice of vitamin and mineral supplements; it has issued regulations to limit the amounts and types of nutrients available in such products. 5 Meanwhile, Jane will learn little or nothing from labels about the potential benefits of vitamin, mineral, or herbal supplements; FDA, in the midst of a self-proclaimed "war against quackery," is aggressively fighting virtually all health-related claims for these products. 6 When Jane is suffering from seasonal allergies, recurring acid indigestion, a vaginal yeast infection, or severe diarrhea, she is unlikely to find much relief from an over-the-counter medicine, so she probably has to visit a doctor to obtain a prescription. Jane knows little or nothing about the remedies the doctor prescribes or their alternatives. Her physician likely does not discuss such issues with her in detail, and the only written information Jane receives about these drugs are the basic directions for use on the dispensing labels. Moreover, Jane cannot easily educate herself about pharmaceutical products. She has almost certainly never seen a prescription drug advertisement in print, and she has definitely has never viewed one on television. There is no internet, of course, but there are also no guides to prescription medicines available in regular bookstores.
FDA's process of approving food ingredients and drugs is entirely foreign to Jane-the exclusive domain of government bureaucrats and scientific experts. Neither Jane nor anyone she knows has ever sought to influence federal food and drug policy in any way.
Now compare Jane's situation to that of Jason, a consumer in 2013. When he goes to the supermarket, Jason chooses from among a dizzying array of traditional foods, food variants, and variants of variants. Many of these products have been formulated specifically for consumers with particular health concerns. Furthermore, the labeling on food packages imparts abundant health-related information to Jason, even some explicit disease prevention claims. The dietary 5 21 Fed. Reg. 8521 (June 18, 1966) . These regulations were stayed due to objections. 6 HUTT, MERRILL & GROSSMAN 246-51.
supplement section of the supermarket occupies yards of shelf space and contains an enormous selection of vitamins, minerals, herbs, botanicals, amino acids, and other ingredients. Moreover, the labeling of many of the supplements directly or indirectly promotes their efficacy for diseases and health problems.
For health issues that Jason cannot address adequately through dietary choices and supplement use, the supermarket's over-the-counter drug aisle offers a plethora of potent remedies, many of which used to be available only by prescription. If he must visit his physician, Jason can readily research his condition and potential therapies for it before his appointment, and he may specifically request that his doctor prescribe him a drug that he has learned about through a television advertisement. Jason's doctor is ethically required to discuss
Jason's course of treatment with him, but even if she neglects to do so, Jason will probably learn quite a bit about the drug from written material he receives from his pharmacist when he fills his prescription.
If FDA were ever to attempt, once again, to restrict the availability of dietary supplements, Jason might well send letters or email messages to his representatives in Congress protesting the agency's conduct. If Jason or a relative suffers from a serious disease, he may belong to a patient advocacy group that seeks to influence FDA's decisions regarding pharmaceutical treatments for that condition. As a result of involvement by such organizations, a drug might be available to Jason or his loved one prior to FDA approval, and the agency may ultimately approve it faster, based on less evidence, and in the face of greater risk than would have been the case just thirty years ago.
How do we explain the very different postures of Jane and Jason with respect to FDAregulated products? FDA viewed Jane's cohort-with some justification-as passive, trusting, and ignorant consumers. The federal government, in conjunction with scientists and physicians, rigorously controlled Jane's food and drug supply and restricted information concerning it. By contrast, John has unmediated access to many more products and to much more information about these products. Compared to the consumers of the mid-1960s, today's consumers of food and drugs are free to make choices from among a wider variety of products, informed by a relative deluge of information.
Both cultural and regulatory changes underlie this emergence of the consumer as an active and informed participant in the management of his or her own diet and health. Regulation has shaped culture and culture has shaped regulation; the arrow of influence runs in both directions. In some instances I discuss below, social movements impelled statutory and administrative developments that in turn promoted consumer autonomy. Other regulatory changes I explore were not provoked by popular demand, but they, too, helped shape social perceptions of the consumer's role and provided consumers with the information and product access they needed to embrace this role.
In the portions of this paper in which I examine the direct impact of social movements on food and drug regulation, or in which I more modestly suggest that certain regulatory developments reflected public preferences, I do not intend to deny the importance of corporate influence over food and drug law. Rather, I seek to add a complicating layer of analysis to those scholarly approaches that flirt with economic determinism by advancing explanatory theories such as "regulatory capture" 7 and "rent seeking." 8 It is important to observe that not all of the 7 I will start by considering some broad shifts in society since the mid-1960s, and I will then discuss some specific regulatory developments in the food and drug legal arena that have both reflected and reinforced these cultural developments.
I. CULTURAL AND SOCIETAL DEVELOPMENTS

A. The Loss of Trust
One critical change in American society during the past half century has been the citizenry's declining trust in the leaders of all major national institutions, including the entire complex of bureaucrats and experts who exercise control over the food and drug supply.
The The results of surveys examining Americans' confidence in the country's medical and scientific establishments quite closely track those regarding their trust in the federal government.
In 1966, 73 percent of respondents expressed a "great deal of confidence" in the leaders of medicine. By 1979, this number was just 30 percent. Since then, the results have wavered within a range well below the peak of the mid-1960s. 20 According to another recurring survey, the proportion of Americans voicing "a great deal of confidence" in the leaders of the scientific community fell quite abruptly-from 56 percent to 32 percent-between 1966 and 1971, and it has measured in the high 30s or low 40s ever since. Notably, Americans' trust in large corporations has also experienced an enormous drop between the era of Jane and the era of Jason. Whereas 55 percent of respondents expressed "great confidence" in "major companies" in 1966, only 16 percent stated the same view in 1980.
Since then, this number has ranged primarily between 10 and 20 percent. 22 Presumably, therefore, the public does not favor giving food and drug companies free rein to manufacture and say whatever they want. Indeed, in a 1999 survey, 58 percent of respondents stated that "food and drug regulation" benefitted them "a great deal" or "a fair amount"-a figure higher than that for any other federal government function mentioned in the poll.
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It thus would be too simplistic to assert that Americans' growing cynicism about government and scientific expertise translates to support for the deregulation of food and drugs.
Instead, I suspect, Americans' distrust of major institutions has led them to the following position. On the one hand, they believe that FDA has an important role to play in ensuring the basic safety of products and the accuracy and completeness of labeling and advertising. 24 On the other hand, they generally do not want FDA to inhibit the transmission of truthful information from manufacturers to consumers, and, except in cases in which risk very clearly outweighs benefit, they prefer that the government allow consumers to make their own decisions regarding what to put in their bodies. 
B. The Rights Revolution
The 1970s have also frequently been identified as the period of the "rights revolution."
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Concepts like women's rights, gay rights, environmental rights, disability rights, and consumer rights dominated the national conversation. 26 And, as discussed below, this "rights talk"
extended forcefully into the world of health and medicine.
Although the "rights revolution" may have peaked in the 1970s, the phenomenon actually occupied a broader period. 27 The various rights movements of the 1970s undeniably built on the racial civil rights movement of the prior decade. 28 In Today, of course, the significance of these books about prescription drugs pales in comparison to that of the internet. The internet revolution has made is it easy for anyone to find detailed medical information, including information about prescription drugs. As early as 1998, there were more than 14,000 health-related websites. 53 The attempted taming of this universe of information began on October 5, 1998, when a young entrepreneur named Jeffrey Arnold advanced search engine technology has reduced the importance of websites such as WebMD. In a 2012 survey, 59 percent of American adults reported looking for health information on the internet in the previous year, and 35 percent said they had used the internet to diagnose a medical condition for themselves or someone else, but many more of these "online health seekers" started their research on internet search engines (77%) than on a site that specialized in health information (13%).
II. REGULATORY DEVELOPMENTS FOR FOOD AND DIETARY SUPPLEMENTS
The cultural and societal developments discussed above help illuminate the FDA regulatory developments explored below-regulatory developments that themselves likely reinforced these cultural and societal trends. I will first examine the empowerment of consumers in the realm of food and dietary supplements, and then the same phenomenon with respect to drugs.
A. Standards of Identity and Labeling
The shift in FDA's perception of the role and capacity of the consumer is reflected in the legal standard it has used to determine whether a product is "false or misleading in any applied, but some of its enforcement actions were clearly designed to protect "gullible consumers" rather than "reasonable" ones. 59 Court interpretations varied, with some holding that the law should protect "the ignorant, the unthinking and the credulous," and others embracing an "ordinary person standard." 60 In 2002, however, FDA unambiguously declared-at least with respect to food-that it would use a "reasonable consumer" standard to determine whether labeling is misleading. 61 The agency explained, "The reasonable consumer standard more accurately reflects FDA's belief that consumers are active partners in their own health care who behave in health promoting ways when they are given accurate health information."
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The rise of the empowered consumer is further illustrated by the evolution of FDA's food standard and nutritional labeling policies. As noted in the introduction, through the late 1960s,
FDA's regulation of the quality and identity of food depended largely on its use of strict, recipestyle standards of identity issued pursuant to section 401 of the federal Food, Drug, and Cosmetic Act ("FD&C Act"). 63 The agency strictly applied the statutory requirement that a variant of a standardized food that "purported to be" the food must be named with the commercially poisonous modifier "imitation. defining nutrient descriptors (such as "no cholesterol," "low sodium," and "reduced fat").
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Pursuant to its NLEA authority, FDA issued a "generic standard of identity," according to which manufacturers may appealingly and informatively name (without a term such as "imitation" or "substitute") standardized foods that have been reconstituted to satisfy one of these nutrient descriptors. 75 Perhaps most dramatically, the NLEA authorized the use of FDA-approved claims substance and a reduced risk of a particular disease. 76 Today, largely as a result of these amendments, a box of Cheerios® often bears detailed nutritional and health information for the consumer on almost every panel.
The proliferation of health claims in food labeling, along with their appearance in advertising and other media, has almost surely transformed the relationship between consumers and food. In 1998, just five years after FDA published its first set of approved health claims, about half of food shoppers reported that their grocery purchase decisions were influenced by their desire to manage or treat specific health conditions. More than half stated that their food choices were influenced by their efforts to reduce the risk of particular health conditions or illnesses.
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NLEA's legalization of the use of health claims was even more significant than it first appeared to be, for it was the issue through which commercial free speech doctrine-now revolutionizing food and drug law-was introduced into the field. For a surprisingly long time, the food industry failed to argue that the regulation of labeling-about half of FDA's mission- are inherently misleading because they have such an awesome impact on consumers as to make it virtually impossible for them to exercise any judgment at the point of sale. It would be as if the consumers were asked to buy something while hypnotized, and therefore they are bound to be misled. We think this contention is almost frivolous.
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Moreover, while acknowledging that the prevention of consumer fraud is a "substantial government interest" that is "directly advanced" by the NLEA health claims regime, the court held that FDA's total ban on claims with less than "significant scientific agreement" is unreasonable, and thus unconstitutional, if the claims can be rendered nonmisleading through accurate disclaimers. The court held that the First Amendment favors disclosure over outright suppression, even in the commercial realm, and it rejected the notion that "the public is not sophisticated enough" to be trusted with correct information. so long as they are adequately qualified by disclaimers. 83 Pearson impelled the agency to establish a new system for reviewing and allowing "qualified health claims." Although FDA asserts that when it permits such claims, it does so as an exercise of its "enforcement discretion," it actually has no choice but to allow them. The list of permissible "qualified health claims" is now twice as long as the list of NLEA "unqualified" health claims.
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B. Citizen Movements
It is difficult, perhaps impossible, to quantify the degree to which the particular regulatory changes discussed above have been driven by popular demand as well as by evolving expert judgment and jurisprudential developments. Occasionally, however, citizens have mobilized to influence an FDA decision in a way that leaves no doubt about the important role of public opinion. The very first mass movements regarding FDA policy that I have identified occurred during the pivotal decade of the 1970s. They both concerned food products-vitamin and mineral supplements and the artificial sweetener saccharin. Nonetheless, their underlying message-that the public should be free to make its own risk-benefit judgments-would flow over into the drug arena as well. Watergate, the energy crisis, and the economy, one of the four issues that generated the most mail to Congress in 1973.
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In 1974 testimony supporting Congressional intervention, David King, the legislative counsel for the National Nutritional Foods Association, a health food industry trade group, voiced a regulatory philosophy that seemed to reflect the views of a broad swath of Americans.
Attacking the provision of the FDA rule declaring supplements with more than 150% RDA potency to be drugs, King opined:
The American concept is that consumers must not only be free to choose, but free to have that choice uninfluenced by government interference…. This is particularly true where the government's evidence in support of its value judgment is sharply contested by a number of experts of impeccable reputation….
As long as he is not dealing with dangerous or untruthfully labeled food, then risktaking [sic] should be for each man to decide for himself….
What purpose is there in discouraging [a hypothetical arthritis] sufferer from pursuing his quest for better health? He is a free man. He is not stupid. … It seems to me that this will be a better country if people are encouraged, rather than discouraged, from interesting themselves in various approaches to health through better nutrition.
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The next day, the U.S. 1977) . 115 Id. See also testimony of Dr. McCann: "Saccharin is primarily a matter of public opinion, and I think that is a respectable thing for it to be, frankly." McCann continued by noting that a decision not to ban the sweetener would not be a scientific decision, but "may well be based on the fact that people want it, want to be able to take a risk, and I see nothing wrong with that." Id.
III. REGULATORY DEVELOPMENTS FOR DRUGS
A. Labeling and Advertising
The consumer's relationship to drugs obviously differs from his or her relationship to
food. An ill person is vulnerable almost by definition, and he is thus more likely to seek expert advice and professional assistance. Moreover, the science of medicine seems more complex and inaccessible to the average person than does the science of nutrition. Finally, as a practical matter, contemporary health care routinely involves the use of drugs and devices that a patient cannot take advantage of without professional intervention. Nevertheless, even within the world of modern orthodox medicine, a consumer can assume a range of roles. A significant difference exists between a patient who is a passive subject of a physician's ministrations and one who is an informed and empowered participant in one's own treatment. The last half century has witnessed a general shift from the former to the latter.
This development is reflected in FDA's regulation of the information provided to patients about prescription drugs. A patient cannot have significant agency in the decision to use a prescription drug unless she is provided with detailed facts about the drug itself. As discussed above, information about prescription drugs has in recent years become markedly more accessible to ordinary consumers through mass market publications and the internet. In this section, I will discuss how the past few decades have also seen an almost revolutionary shift in FDA's views about patient labeling and direct-to-consumer advertising of prescription drugs. Nonetheless, the agency maintained its position that prescription drug information should be directed only to physicians and other medical professionals. The FDA did not mandate or even encourage any patient-directed labeling for prescription drugs until 1968, when it required a two sentence warning statement to appear on the container of a self-administered inhalation drug product.
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The issue of patient labeling for prescription drugs became a matter of public debate in 1970, when FDA proposed to require patient package inserts for oral contraceptives. These inserts would set out, "in lay language," the risks and possible side effects associated with the use of the pill. 121 The wording of the proposed rule itself reveals the caution with which the agency took this then-revolutionary action.
[T]he administration has reviewed the oral contraceptive products, taking into account the following factors: the products contain potent steroid hormones which affect many organ systems; they are used for long periods of time by large numbers of women who, for the most part, are healthy and take them as a matter of choice … in full knowledge of other means of contraception; and because of their indications they are sometimes used without adequate medical supervision. They represent, therefore, the prototype of drugs for which well-founded patient information is desirable.
… The Commissioner … is aware that this represents a departure from the traditional approach to the dissemination of information regarding prescription drugs via the doctor/patient relationship, and stresses that it is not intended to weaken or replace that channel, but rather because of the unusual pattern of use by [sic] these drugs, to reinforce the efforts of the physician to inform the patient in a balanced fashion of the risks attendant upon the use of oral contraceptives. to their patients about the use of estrogens and the accuracy of the compulsory labeling, the court continued:
… [I]t becomes apparent that the plaintiffs urge recognition not of a right to exercise judgment in prescribing treatment, but rather of a right to control patient access to information…. There simply is no constitutional basis for recognition of a right on the part of physicians to control patient access to information concerning the possible side effects of prescription drugs. … The physician rights discussed [in cases cited by the plaintiffs] are … derivative of patient rights and do not exist independent of those rights. …
The patient rights recognized in the line of cases relied upon by plaintiffs flow from a constitutionally protected right of privacy…. To the extent these cases have any bearing on the present issue, then, their rationale would appear to support the challenged regulation. The objective of that regulation is to provide the patient with the facts relevant to a choice about the use, and manner of use, of estrogen drugs. The asserted right to limit patient access to such information can hardly be said to facilitate the patient's "interest in independence" in decision making. taken," it explained in the preamble, "because FDA believes that prescription drug labeling that is directed to patients will promote the safe and effective use of prescription drug products and that patients have a right to know about the benefits, risks, and directions for use of the 
B. Direct-to-Consumer Advertising
Neither the FD&C Act nor FDA regulations have ever expressly prohibited direct-toconsumer (DTC) advertising of prescription drugs. Nonetheless, until the early 1980s, no drug manufacturer had ever promoted such a product directly to consumers. In fact, the industry viewed the practice as "inconceivable." 135 As one scholar has noted:
From a historical perspective, the concept of promoting prescription drugs directly to the ultimate consumer, the patient, has a distinctly radical element to it…. DTC advertising and promotion … undermine our most historic principles of disease management and professional relations. Since there have been physicians, there has been a mystique about how they manage disease…. This attitude extends to the products prescribed or used by the physician. 136 The majority of doctors, including physicians within FDA, considered DTC advertising of prescription drugs to be simply inappropriate. 137 According to surveys conducted in 1984, 69 percent of physicians were opposed to all DTC prescription drug advertising and 84 percent opposed such advertising on television. 138 Many doctors believed that DTC promotion would interfere with the physician-patient relationship. 139 Indeed, when FDA first proposed to allow the advertising merely of prescription drug prices directly to consumers, it received comments "express [ing] concern that encouragement of prescription drug price advertising would promote self-medication and self-prescribing and lead to drug abuse and misuse by consumers who pressure their physicians to prescribe larger quantities and cheaper drugs."
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Drug companies, with their well-established channels of promotion to physicians, generally agreed that DTC advertising was improper. 141 Moreover, manufactures widely assumed that DTC advertising campaigns would not work in any event. They believed that a DTC campaign for a prescription drug would be "suicidal" because "doctors never would accept a program that bypassed them."
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Despite these forces aligned against DTC advertising, two direct-to-consumer advertisements appeared in print publications in the early 1980s. 143 Then, in February 1983, FDA Commissioner Arthur Hull Hayes, Jr. delivered a speech to the Pharmaceutical Advertising
Council that has been characterized as perhaps "the most important speech ever made by a commissioner." 144 In this address, Hayes predicted "exponential growth" in DTC advertising
and thus unintentionally sent a signal that FDA would be open to such promotion. 145 The agency soon began receiving numerous proposed DTC advertisements. 146 In September 1983, Hayes, concerned that DTC advertising of prescription drugs had not been adequately researched or discussed, requested a voluntary moratorium on the practice "in order to permit time for a reasoned assessment of this complex issue." In any event, DTC advertising is now a largely accepted component of the fabric of American commercial culture. And the shifting societal mores that made DTC advertising 154 Patient and Physician Attitudes Survey at 25. Broadcast advertisement are not required to include the entire brief summary, but instead may make "adequate provision for dissemination of the approved or permitted package labeling in connection with the broadcast presentation." 21 C.F.R. 202.1(e)(1). In 1997, FDA set forth in a guidance document a set of acceptable steps an advertiser can take to comply with this "adequate provision" requirement, including, for example, providing a web address, a toll-free number, and a reference to a contemporaneously available print advertisement. Draft Guidance for Industry: Consumer-Directed Broadcast Advertisements (1997). 155 In the 1990s, the Pharmaceutical Research and Manufacturers of America unambiguously embraced DTC advertising, and the American Medical Association officially accepted it, though with reservations. Pines at 508-509. 156 Pines at 491-92. 157 Pines at 492 (this study "shaped FDA's thinking at the time about DTC advertising"); Morris et al. at 86. Consumers at the time appear to have been much more resistant to television advertising of prescription drugs than print advertising; in the same study, 46 percent of respondents agreed wit the statement "I think teleivion commercials for prescription drugs would be a bad idea." Id. at 86. 158 Trento, text accompanying note 22.
possible have in turn been shaped by this advertising. In surveys conducted by FDA, approximately half of respondents indicated that a DTC advertisement had prompted them to look for more information about a drug or their health. 159 Moreover, 85 percent of physicians stated that their patients often asked them about prescription drugs, and they overwhelmingly reported that these questions had increased in frequency since the introduction of broadcast advertisements. 160 Most of these patient-initiated discussions about prescription drugs concerned particular brand name products, which patients routinely asked their doctors to prescribe. 161 One can only imagine how outlandish such interactions would seem to a doctor of the 1950s.
The rise of DTC advertising for prescription drugs is an American story. Only one other nation in the world-New Zealand-permits the manufacturers of these products to trumpet their efficacy directly to consumers.
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C. Prescription versus OTC Status
Another factor within FDA's zone of authority that greatly affects the respective roles of patient and doctor is a drug's status as either a prescription or over-the-counter (OTC) product. approval of such switches responds to a "growing desire of consumers to have greater control over their health care" and to "the 'self-care' movement." 174 Moreover, the recent controversies over the OTC switch application and petition for the "Plan B" emergency contraceptive demonstrates the potential for such switches to stir popular passions in at least some instances.
Due largely to the unique characteristics of that product, the Plan B dispute represented perhaps the first instance in which switch advocates have contended that consumers have a right to access a drug without a prescription.
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In any event, the switch phenomenon of the past few decades reflects FDA's embrace of a modern vision of consumers as autonomous, capable guardians of their own health.
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Furthermore, the very availability of such fundamental therapies on an over-the-counter basis has doubtless reinforced this view among consumers themselves.
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D. Citizen Movements
Finally, during the past few decades, the lay population has assumed a greater role in pressuring FDA to make drugs more quickly and more broadly accessible to the seriously ill.
Ordinary citizens had little involvement in FDA product approval decisions before the 1970s.
These processes were the exclusive domain of experts from inside and outside the government, economically interested companies, and, sometimes, sophisticated consumer organizations. But, as discussed above, the 1970s saw the rise of citizen movements for vitamin and saccharin access. Shortly after the successful culmination of these campaigns, masses of regular people organized to resist FDA's ban on another product-an alternative cancer treatment derived from apricot pits called Laetrile (amygdalin).
FDA had been scuffling with purveyors of Laetrile since the early 1960s. 178 opponents to the whole drug regulatory process, the conservatives … who believed that the government should not poke its nose into the lives of citizens at all. 195 In 1986, under pressure from AIDS groups, FDA made the unapproved investigational drug AZT available to patients outside of formal clinical trials on a "compassionate use" basis. 196 The next year, FDA approved the new drug application (NDA) for AZT even though the drug had not undergone the large Phase 3 controlled clinical investigations ordinarily required for approval, and even though experts expressed serious doubts about the product's safety and effectiveness. 197 Less than two years passed between the submission of the Investigational New Drug application for AZT and FDA's final approval of the NDA-an astonishingly brief period compared to most drugs. Another sign that the FDA was responding to the activists' demands occurred the very same day in 1987 as the AZT approval. The agency proposed a "Treatment IND" rule that formalized the agency's longstanding ad hoc practice of allowing compassionate use. 198 The rule, finalized two months later, permitted seriously ill people with no satisfactory alternatives to gain access to investigational drugs that "may be effective," although this access was subject to strict limitations designed to ensure that the drug would also be tested in controlled clinical studies. The AIDS groups' impact should not be overstated; although the fast track procedure has been quite successful, treatment INDs remain rare, although not primarily because of agency reluctance to grant them. 213 The activists' influence should not be understated either, however.
Due largely to their efforts, FDA's view of its own mission evolved, and it now embraces the task not only of protecting the public health by preventing the sale of dangerous products, but also of enhancing the public health by ensuring access to useful remedies. b) ) to the FD&C Act, stating that FDA's mission is, first, to "promote the public health by promptly and efficiently reviewing clinical research and taking appropriate action on the marketing of regulated products in a timely manner," and, second, to "protect the public health by assuring that" these products are safe and effective.
risk-benefit balancing, particularly when fatal and disabling diseases are at issue. Although drug approval has not become measurably easier to achieve in the past quarter century, FDA now must deal with this "freedom of choice" rhetoric whenever it is reviewing the NDA for a drug intended to treat an otherwise incurable condition. And in a few prominent instances, the consumer choice argument has prevailed. For example, in response to protests by sufferers of irritable bowel syndrome, the FDA in 2002 permitted the return to the market of Lotronex, a drug earlier withdrawn because of occasional severe side effects. 215 The most recent amendments to the FD&C Act demonstrate how the patient-centered ethos of the AIDS movement continues to shape federal drug regulation today. The Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA) revises the "fast track"
provisions in a way that seems to expand the situations in which accelerated approval is available and also to broaden the surrogate endpoints on which such approval can be based. 216 FDASIA also explicitly invites a more liberal risk-benefit analysis with respect to drugs for severe conditions with no alternative treatments. 217 
